Modulation of Mevalonate-Independent Isoprenoid Biosynthetic Pathway
Inventors: Joseph Noel, Marianne Bowman and Stephane Richard
Potential Uses: Infection, Drug Discovery, Natural Products, Agriculture, Plant Biology
Templates for the design of novel antibacterial and antiparasitic drugs
The invention provides the three dimensional structure of the enzyme 4-diphosphocytidyl-2-C-methylerythritol (CDP-ME) synthase, a member of the cytidyltransferase family of enzymes. CDP-ME is a critical intermediate in the mevalonate-independent pathway for isoprenoid biosynthesis in a number of prokaryotic organisms, in algae, in the plastids of plants and in the malaria parasite. Since vertebrates synthesize isoprenoid precursors using a mevalonate pathway, CDP-ME synthase and other enzymes of the mevalonate-independent pathway for isoprenoid production represent attractive targets for the structure-based design of selective antibacterial, herbicidal and antimalarial drugs. The invention provides methods for screening for compounds that inhibit enzymes of the mevalonate-independent pathway and pharmaceutical compositions and antibacterial formulations thereof. Further provided are methods of inhibiting the enzymes of the pathway and bacterial terpenoid synthesis and methods for treating a subject suffering from a bacterial infection.
Patent Status: U.S. Patent No. 7,286,973 B1 issued October 23, 2007
Publications: Nat Struct Biol 2001 Jul: 8(7):641-8
License Terms: Exclusive or Nonexclusive licenses available
Contact: Robert MacWright, Ph.D., Esq., Director, OTD, 858.453.4100 x1703, rmacwright@salk.edu





